Investing.com -- The momentum factor weakened in December, but more downside can be expected in the first quarter, according to a Jefferies strategist.
investing.com·9mo ago
Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success
This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. FDA.